Review
Copyright ©The Author(s) 2015.
World J Ophthalmol. May 12, 2015; 5(2): 55-72
Published online May 12, 2015. doi: 10.5318/wjo.v5.i2.55
Table 4 Summary of the study using intravitreal Aflibercept for treatment of diabetic macular edema
Name of studyPurposeStudy designOut comes measuresIVA DoseInterval of injectionNaive or refractory /DMEDuration of studyNumber of eyesTreatment regimenResults
DA VINCI[84,85]IVVTE for DMERCTIVA f or DME0.5 and 2 mg1 and 2 moNaïve or refractory1 yr221Group 1 (IVVTE1, n = 44 eyes): IVVTE, 0.5 mg every 4 wk Group 2 (IVVTE2, n = 44 eyes): IVVTE, 2 mg every 4 wk Group 3 (IVVTE3, n = 42 eyes): IVVTE, 2 mg for 3 initial mo then every 8 wk Group 4 (IVVTE4, n = 45 eyes): IVVTE, 2 mg for 3 initial months then as needed Group 5 (L, n = 44 eyes): laser photocoagulation Laser modified ETDRS protocolBCVA changes (letters) P value IVVTE1 +8.6 0.005 IVVTE2 +11.4 < 0.0001 IVVTE3 +8.5 0.008 IVVTE4 +10.3 0.0004 L +2.5 CMT(μm) IVVTE1 -144.6 0.0002 IVVTE2 -194.5 < 0.0001 IVVTE3 -127.3 0.007 IVVTE4 -153.3 < 0.0001 L -67.9